A. Education

1. Academic background

• 2001.3– 2005.3Ph.D. in Molecular Cancer Pharmacology

ZhejiangUniversity, Hangzhou, China

• 1995.9– 1997.7MS in Pharmacology

ZhejiangMedical University, Hangzhou, China

• 1989.9– 1993.7BS in Department of Pharmacy

ZhejiangMedical University, Hangzhou, China

2. Professional Experiences and Affiliations

• 2009.5-now Professor,College of Pharmaceutical Sciences
• 2003.10-2009.4 Associate Professor,College of Pharmaceutical Sciences
• 2002.9 – 2003.10 Research Fellow, Keck School of Medicine, University of Southern California, CA, USA
• 1993.8-2003.10 Lecturer, Department of Pharmacology, School of Pharmaceutical Science, Zhejiang University, Hangzhou, China

B. RESEARCHINTERESTS AND AREAS

• Molecular Cancer Pharmacology: new drugs development based on cancer stem cells and molecular targets;
• Regulation of Cancer Cell Differentiation: post-translational modification of proteins involved in differentiation of leukemia cells;
• Drug Toxicology: new drugspreclinical evaluation, new methods and animal models for Drug toxicologyevaluation, etc.

C.MAIN RESEACH ACHIEVEMENTS

Publishing more than 110 academic articles, including 90 articles in SCI journals. Most of the research articles are published in a number of prestigious and international journals including Molecular Cancer Therapeutics, Cancer Research, FASEB Journal, Stem Cell, PLoS One, Oncogene. Obtaining more than 30 issued patents which are new drug related. Obtaining seven projects of National Natural Science Foundation, 3 items of second prize of “Science and Technology Progress Award of Zhejiang Province”. Accomplishing more than 50 new drug evaluation and development projects for industry companies.

1. REPRESENTATIVE PUBLICATIONS

• Zhou X, Fang Y, Jing H, Zhong L, Luo P, Song H, Yang B, He Q*. Involvement of mitogen-activated protein kinase in signal transducer and activator of transcription-1 mediated differentiation induced by bortezomib in acute myeloid leukemia cells. Mol Carcinog. 2011 Oct 17. doi: 10.1002/mc.20873. [Epub ahead of print]
• Fang Y, Zhou X, Lin M, Ying M, Luo P, Zhu D, Lou J, Yang B, He Q*. Inhibition of all-Trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells. Mol Carcinog. 2011 Jan;50(1):24-35.
• Fang Y, Zhou X, Lin M, Jing H, Zhong L, Ying M, Luo P, Yang B*, He QJ*. The ubiquitin-proteasome pathway plays essential roles in ATRA-induced leukemia cells G(0)/G(1) phase arrest and transition into granulocytic differentiation. Cancer Biol Ther.  2010 Dec 1;10(11):1157-67.
• Zhao Y, Xue T, Yang X, Zhu H, Ding X, Lou L, Lu W, Yang B*, He QJ*. Autophagy plays an important role in Sunitinib-mediated cell death in H9c2 cardiac muscle cells.Toxicol Appl Pharmacol. 2010 Oct 1;248(1):20-7. 
• He QJ, Peng H, Collins SJ, Triche TJ, Wu L*. Retinoid-modulated MAT1 ubiquitination and CAK activity. FASEB J. 2004.11:1734-6.  

2. GRANTS

• National Natural Science Foundation of China  (2011–2013)

The effect of hypoxia in tumor-specific inflammation enhanced tumorgenesis

• National Science and Technology Major Project”Major New Drug Discovery” Special Program (2009–2011)
• National Natural Science Foundation of China  (2010-2012):

Synergistic anti-tumor activity of proteasome inhibitors and retinoic acid by inducing cancer cell differentiation

• National Natural Science Foundation of China  (2008–2010)

The effect of CAK phosphorylation on the ubiquitin related degradation of proteins during retinoic acid induced leukemia cell differentiation.

• National Natural Science Foundation of China  (2006–2008)

The role of ubiquitin proteasome pathway in the retinoic acid induced leukemia cell differentiation.

3. BOOKS

• “Basic Pharmacology”, Higher Education Press, 2006.6.
• “Pharmacy Test Problem Book”, Peking Union Medicai College Press
• “Textbook of Molecular Pharmacology”, Higher Education Press, 2007.6.
• “Medicine Mathematical Statistics Method”, People's Medical Publishing House, 2007.8
• “Medicine Mathematical Statistics Method Problem Book”, People's Medical Publishing House, 2007.8

4. PATENTS

• New Drug Certification (Chinese materia medica): Z20010084（2001.5）. This certification has been transferred to a Pharmaceutical company.
• Clinical Trial Approval: 2001XL0194;
• A Patent formally put into production: ZL 02 1 10648.7;
• 31 authorized Patents for novel compounds.

D. HONORS & AWARDS

• The second batch of high-level innovative talents of Zhejiang Province (2008, 2010, 2011)
• New-Century Talented Scientist by the Chinese Ministry of Education
• Chinese Pharmacological Society Servicer Award for young workers in Pharmacology.
• Second level of 151 Talent Project of Zhejiang Province.
• Technology Award for young workers in Zhejiang Province